La Jolla Pharmaceutical Co. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone. The LJPC-30Sa and LJPC-30Sb are the next generation gentamicin derivatives, which is an antibiotic for kidney toxicity. The company was founded in 1989 and is headquartered in San Diego, CA.
